Oxford Nanopore Technologies vs Umoja Biopharma
Side-by-side comparison of AI visibility scores, market position, and capabilities
UK nanopore sequencing pioneer with portable MinION device; £223M FY2025 revenue (+24% constant currency). Clinical revenues up 60% as sequencing moves to point-of-care.
About
Oxford Nanopore Technologies (ONT) was spun out of the University of Oxford in 2005, commercializing a radically different sequencing approach: passing DNA strands through biological nanopore proteins embedded in a membrane and detecting characteristic ionic current changes to call bases in real time. This enables ultra-long reads (megabase scale), direct RNA sequencing, and epigenetic base modification detection without prior amplification.\n\nONT's product range spans from the palm-sized MinION (the world's first portable DNA sequencer) to the high-throughput PromethION 2 Solo and PromethION 48 platforms. These instruments have enabled field sequencing for infectious disease outbreak response (COVID-19, mpox, Ebola), real-time clinical microbiology, plant pathogen surveillance, and cancer genomics. The company reported £223 million in FY2025 revenue, representing 24% constant-currency growth, with clinical revenues up 60% and biopharma revenues up 30%.\n\nONT is publicly listed on the London Stock Exchange and holds approximately £300 million in cash. While accuracy has historically lagged Illumina and PacBio, successive chemistry improvements and the Kit14 chemistry have closed the gap for many applications. The company is expanding its presence in clinical diagnostics, with regulatory filings underway in key markets, and remains the benchmark for portable, real-time, and long-read sequencing.
Umoja Biopharma raised $300M+ for its lentiviral vector CAR-T platform that delivers cancer-fighting T-cells in a single IV infusion, eliminating the need for cell extraction and manufacturing.
About
Umoja Biopharma is developing an in vivo CAR-T cell therapy platform that circumvents the costly and time-consuming ex vivo manufacturing process that limits current CAR-T therapies. Instead of extracting a patient's T-cells, engineering them in a lab, and reinfusing them, Umoja's approach delivers viral vectors intravenously that reprogram T-cells directly inside the patient's body. This could reduce CAR-T therapy costs from $400,000+ to a fraction of that price.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.